ArticleCureus2026
Progressive Slurred Speech as an Atypical Presentation of GDAP2-Related Spinocerebellar Ataxia: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 47-year-old man with diabetes mellitus and dyslipidemia developed progressive slurred speech over four years. MRI revealed no cerebellar atrophy, and routine laboratory and neurophysiological investigations were unremarkable. His brother exhibited similar but advanced symptoms, including dysphagia and severe gait impairment, leading to wheelchair dependence. Whole-exome sequencing identified a likely pathogenic homozygous nonsense mutation in the GDAP2 gene, confirming a diagnosis of autosomal recessive spinocerebellar ataxia type 27 (SCAR27). This report emphasizes the importance of considering hereditary ataxias in the differential diagnosis of progressive dysarthria, even in the absence of striking ataxic signs or neuroimaging abnormalities. Early genetic testing can prevent unnecessary investigations, facilitate appropriate counselling, and improve the understanding of rare neurological conditions. Identifying novel mutations contributes to delineating the full clinical spectrum of SCAR27 and may guide research into targeted therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.